DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination.
Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer
and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase
(PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway
is of extreme importance for further understanding cancer development and therapeutic
vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a
key role in homologous recombination by stimulating end resection at double-strand breaks.
EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand crosslinking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in
BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA
repair whose inactivation phenocopies BRCA1 deficiency, Surrallés laboratory is supported by the ICREA-Academia program, the Marató de TV3 (project 464/C/2012), the Spanish Ministry of Health (projects FANCOSTEM and FANCOLEN), the Spanish Ministry of Economy and Competiveness (projects CB06/07/0023, SAF2012-31881, SAF2013-45836-R and SAF2015-64152-R), the European Commission (EUROFANCOLEN project HEALTH-F5-2012-305421 and P-SPHERE COFUND project), the Fanconi Anemia Research Fund Inc., and the “Fondo Europeo de Desarrollo Regional, una manera de hacer Europa” (FEDER). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain. This work was also supported by grants from the Asociación Española Contra el Cáncer (AECC, Hereditary Cancer group, 2010), the Generalitat de Catalunya (SGR 2014-364 and 2014-338), and the Instituto de Salud Carlos III (PIE13/00022-ONCOPROFILE, CP10/00617, PI10/01422, PI12/02585, PI13/00285, PI15/00854, PI16/00563, PI16/01218, and RTICC RD12/0036/0008). S.G.-E. is funded by a Miguel Servet contract from the Instituto de Salud Carlos III., Peer reviewed
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2012-31881
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2013-45836-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2015-64152-R
,
EC / FP7 305421
,
EC / H2020 665919
View at: http://hdl.handle.net/10261/180508